Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT06010875 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start date: November 30, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.

NCT ID: NCT06002126 Recruiting - HIV Infections Clinical Trials

Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries

Start date: August 2, 2023
Phase: N/A
Study type: Interventional

Cervical cancer is a relatively common cancer among women living with human immunodeficiency virus (HIV). This study will test women for human papillomavirus (HPV) infection of the cervix. The main purpose of this study is to determine the best way to test for damaged areas of the cervix. Damaged areas of the cervix should be treated and removed to prevent cancer of the cervix. Women in this study will be seen once, twice or three times in a year. Women will provide several samples related to screening for cervical cancer including a swab of the cervix, a self-collected swab of the vagina and urine. Women will have a detailed examination of the cervix called colposcopy and have a few biopsies, or small pinches of the cervix, to look for areas at risk for turning into cancer. If HPV of the cervix is found but treatment of the cervix is not indicated, women will return in 6 months and in 12 months to repeat these tests. Most women will only need 1 visit. Women found to have damaged areas of the cervix at risk for turning into cancer will be referred for treatment. This protocol will compare different tests to understand the best test to identify women at risk for cervical cancer.

NCT ID: NCT05996783 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial

ScreenUrSelf
Start date: May 25, 2023
Phase: N/A
Study type: Interventional

The goal of the ScreenUrSelf trial is to increase cervical cancer screening attendance and compliance to follow-up by offering a first-void urine self-sampling alternative to women who are currently not participating in the organized cervical cancer screening program (defined in this project as un(der)-screened women), either on the woman or her physician's personal initiative, or by responding on the invitation letter.

NCT ID: NCT05994300 Recruiting - Cervical Neoplasm Clinical Trials

Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer

Start date: September 19, 2023
Phase: N/A
Study type: Interventional

External radiation given in 25 fractions or so together with weekly chemotherapy and followed by 5 or 6 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. We hope to develop external moderately hypofractionated radiotherapy of cervical cancer based on adaptive radiotherapy.The objective of this study is to evaluate the efficacy and treatment-related toxicity of moderately hypofractionated adaptive radiotherapy in the treatment of cervical cancer.

NCT ID: NCT05990803 Recruiting - Cervical Cancer Clinical Trials

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Start date: November 6, 2023
Phase: Phase 2
Study type: Interventional

Objective: To explore the efficacy, safety and tolerability of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in patients with recurrent or metastatic cervical cancer and other gynecological malignancies, and to further explore the optimal dose and mode of combination.

NCT ID: NCT05990270 Recruiting - HPV Infection Clinical Trials

The Effect of Education Given to Women on Cervical Cancer on Knowledge, Attitude and Belief

EEWCCKAB
Start date: August 15, 2023
Phase: N/A
Study type: Interventional

Aim: The aim of this study is to reveal the effect of education given to women about cervical cancer on knowledge, attitude and belief. Material and Method: This randomized controlled study was conducted with 130 who had a public hospital located in Southeast Turkey (51 experimental, 51 control).

NCT ID: NCT05975593 Recruiting - Pancreatic Cancer Clinical Trials

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

METEOR-CRATR
Start date: December 19, 2023
Phase:
Study type: Observational

This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment (imaging, dosimetry, clinical) data before, during, and after treatment with definitive-intent standard of care (SOC) radiotherapy for patients with locally advanced cervical and pancreatic cancer.

NCT ID: NCT05968183 Recruiting - HIV Seropositivity Clinical Trials

The Value of HPV Testing for Cervical Cancer Screening in Women Living With HIV (PAPILLO-VIH)

PAPILLO-VIH
Start date: July 1, 2023
Phase:
Study type: Observational

The main objective of this study is to evaluate the interest of a screening strategy based on the HPV test in patients living with HIV, compared to the cell smear alone in the same population. The Secondary objective of this study is to verify if the use of HPV testing could allow for a longer follow-up of these patients in case of negativity, and thus allow for a standardization of clinicians' practices.

NCT ID: NCT05952141 Recruiting - Cervical Cancer Clinical Trials

Strategies to Close the Gap From CC Diagnosis to Treatment in Botswana

Start date: September 18, 2023
Phase: N/A
Study type: Interventional

Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a pragmatic trial design.

NCT ID: NCT05950087 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy

Start date: November 1, 2022
Phase:
Study type: Observational

Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.